Literature DB >> 11712085

Expression and function of adrenomedullin and its receptors in Conn's adenoma cells.

M Forneris1, L Gottardo, G Albertin, L K Malendowicz, G G Nussdorfer.   

Abstract

Adrenomedullin (ADM) is a hypotensive peptide, that derives from the proteolytic cleavage of pro(p)ADM and acts through two subtypes of receptors, called L1-receptor (L1-R) and calcitonin receptor-like receptor (CRLR). CRLR may function as a calcitonin gene-related peptide or a selective ADM receptor depending on the expression of the subtype 1 or the subtypes 2 and 3 of a family of proteins, named receptor-activity modifying proteins (RAMPs). Reverse transcription (RT)-polymerase chain reaction (PCR) allowed the detection of pADM mRNA in dispersed cells of eight Conn's adenomas (aldosteronomas). These cells also expressed peptidyl-glycine alpha-amidating monooxigenase, the enzyme converting immature ADM to the mature form, and contained sizeable amounts of ADM-immunoreactivity as measured by radioimmunoassay. RT-PCR also demonstrated the presence in aldosteronoma cells of the specific mRNAs of L1-R, CRLR and RAMPs 1-3. ADM (10(-8) M) inhibited angiotensin-II (10(-9) M)-simulated aldosterone secretion from cultured aldosteronoma cells, without affecting basal production. ADM (10(-8) M) also enhanced basal proliferation rate of cultured cells, as estimated by the 5-bromo-2'-deoxyuridine immunocytochemical technique. Both effects of ADM were annulled by the ADM-receptor selective antagonist ADM22-52 (10(-7) M). In conclusion, our study provides evidence that aldosteronoma cells express both ADM and ADM22-52-sensitive receptors. These findings, coupled with the demonstration that ADM exerts an aldosterone antisecretagogue action and a proliferogenic effect on cultured aldosteronoma cells, make it likely that endogenous ADM system plays a potentially important role in the paracrine or autocrine functional control of Conn's adenomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11712085     DOI: 10.3892/ijmm.8.6.675

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  4 in total

1.  Pathophysiological functions of adrenomedullin and natriuretic peptides in patients with primary aldosteronism.

Authors:  Wei Hu; Pang-hu Zhou; Xiao-bin Zhang; Chang-geng Xu; Wei Wang
Journal:  Endocrine       Date:  2014-06-11       Impact factor: 3.633

Review 2.  Adrenomedullin and tumour microenvironment.

Authors:  Ignacio M Larráyoz; Sonia Martínez-Herrero; Josune García-Sanmartín; Laura Ochoa-Callejero; Alfredo Martínez
Journal:  J Transl Med       Date:  2014-12-05       Impact factor: 5.531

Review 3.  Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy.

Authors:  Ramiro Vázquez; Maria E Riveiro; Caroline Berenguer-Daizé; Anthony O'Kane; Julie Gormley; Olivier Touzelet; Keyvan Rezai; Mohamed Bekradda; L'Houcine Ouafik
Journal:  Front Oncol       Date:  2021-01-06       Impact factor: 6.244

Review 4.  Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.

Authors:  Toshihiro Kita; Kazuo Kitamura
Journal:  Hypertens Res       Date:  2022-01-06       Impact factor: 5.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.